Low-Dose Radiation Potentiates the Therapeutic Efficacy of Folate Receptor-Targeted Hapten Therapy

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 2, 2008, Pages 559-566

  Sega, Emanuela I ^a   Lu, Yingjuan ^b   Ringor, Michael ^c   Leamon, Christopher P ^b   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

^b Endocyte Inc   (United States)

^c Faith Hope and Love Cancer Center   (United States)

Author keywords

Cancer immunotherapy; Combined modality therapies; Folate receptor; Low dose radiation; Targeting of folate hapten conjugates

Indexed keywords

CELLS; IMMUNOLOGY; RADIOTHERAPY; TUMORS; VITAMINS;

CANCER IMMUNOTHERAPY; COMBINED-MODALITY THERAPIES; FOLATE RECEPTOR; LOW-DOSE RADIATION;

ONCOLOGY;

ALPHA INTERFERON; FLUORESCEIN ISOTHIOCYANATE; FOLATE RECEPTOR; FOLIC ACID; HAPTEN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; IMMUNE SYSTEM; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION DOSE; RAT; SKIN TUMOR; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FOLIC ACID; HAPTENS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RANDOM ALLOCATION; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 43049167382     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.02.010     Document Type: Article

References (50)

1. Mitchell M.S. Cancer vaccines, a critical review-Part I. Curr Opin Investig Drugs 3 (2002) 140-149
2. Mitchell M.S. Cancer vaccines, a critical review-Part II. Curr Opin Investig Drugs 3 (2002) 150-158
3. White C.A., Weaver R.L., and Grillo-Lopez A.J. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 52 (2001) 125-145
4. Foss F.M. Immunologic mechanisms of antitumor activity. Semin Oncol 29 (2002) 5-11
5. Costello R.T., Gastaut J.A., and Olive D. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz) 47 (1999) 83-88
6. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3 (2002) 999-1005
7. Restifo N.P., Esquivel F., Kawakami Y., et al. Identification of human cancers deficient in antigen processing. J Exp Med 177 (1993) 265-272
8. Igney F.H., and Krammer P.H. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 71 (2002) 907-920
9. Chang E.Y., Chen C.H., Ji H., et al. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 86 (2000) 725-730
10. Yei S., Bartholomew R.M., Pezzoli P., et al. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: Generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Gene Ther 9 (2002) 1302-1311
11. Dessureault S., Graham F.L., and Gallinger S. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells. Cancer Gene Ther 6 (1999) 195-208
12. Putzer B.M., Hitt M., Muller W.J., et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci U S A 94 (1997) 10889-10894
13. Chiriva-Internati M., Grizzi F., Pinkston J., et al. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 42 (2006) 89-95
14. Dalgleish A., and Pandha H. Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv Cancer Res 96 (2007) 175-190
15. Gattinoni L., Powell Jr. D.J., Rosenberg S.A., et al. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 6 (2006) 383-393
16. Weitman S.D., Lark R.H., Coney L.R., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52 (1992) 3396-3401
17. Toffoli G., Cernigoi C., Russo A., et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74 (1997) 193-198
18. Bueno R., Appasani K., Mercer H., et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 121 (2001) 225-233
19. Ross J.F., Wang H., Behm F.G., et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85 (1999) 348-357
20. Lu Y., and Low P.S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51 (2002) 153-162
21. Lu Y., Sega E., and Low P.S. Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer 116 (2005) 710-719
22. Lu Y., Xu L.C., Parker N., et al. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. Mol Cancer Ther 5 (2006) 3258-3267
23. Owen J.B., Coia L.R., and Hanks G.E. Recent patterns of growth in radiation therapy facilities in the United States: A patterns of care study report. Int J Radiat Oncol Biol Phys 24 (1992) 983-986
24. Friedman E.J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8 (2002) 1765-1780
25. Nikitina E.Y., and Gabrilovich D.I. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: Approach to treatment of advanced stage cancer. Int J Cancer 94 (2001) 825-833
26. Ganss R., Ryschich E., Klar E., et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62 (2002) 1462-1470
27. Quarmby S., Hunter R.D., and Kumar S. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res 20 (2000) 3375-3381
28. Reddy J.A., Westrick E., Vlahov I., et al. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 58 (2006) 229-236
29. Chen Z., Moyana T., Saxena A., et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 93 (2001) 539-548
30. Kotera Y., Shimizu K., and Mule J.J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61 (2001) 8105-8109
31. Melcher A., Gough M., Todryk S., et al. Apoptosis or necrosis for tumor immunotherapy: What's in a name?. J Mol Med 77 (1999) 824-833
32. Pulaski B.A., and Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58 (1998) 1486-1493
33. Hartmann L.C., Keeney G.L., Lingle W.L., et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121 (2007) 938-942
34. Amato RJ, Hernandez-McClain J, Conley B, et al. A phase Ib study of FolateImmune (EC90 with GP1-0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-α (IFN-α) in patients with refractory or metastatic cancer. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition);25:13516.
35. Demaria S., Bhardwaj N., McBride W.H., et al. Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 63 (2005) 655-666
36. Klein B., Loven D., Lurie H., et al. The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture. J Neurosurg 80 (1994) 1074-1077
37. Santin A.D., Hiserodt J.C., Fruehauf J., et al. Effects of irradiation on the expression of surface antigens in human ovarian cancer. Gynecol Oncol 60 (1996) 468-474
38. Vereecque R., Buffenoir G., Gonzalez R., et al. Gamma-ray irradiation induces B7.1 expression in myeloid leukaemic cells. Br J Haematol 108 (2000) 825-831
39. Hallahan D.E., Staba-Hogan M.J., Virudachalam S., et al. X-Ray-induced P-selectin localization to the lumen of tumor blood vessels. Cancer Res 58 (1998) 5216-5220
40. Hallahan D., Kuchibhotla J., and Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 56 (1996) 5150-5155
41. Ryschich E., Harms W., Loeffler T., et al. Radiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat. Int J Cancer 105 (2003) 506-511
42. Ishihara H., Tsuneoka K., Dimchev A.B., et al. Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 133 (1993) 321-326
43. Hallahan D.E., Spriggs D.R., Beckett M.A., et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A 86 (1989) 10104-10107
44. Hong J.H., Chiang C.S., Tsao C.Y., et al. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 75 (1999) 1421-1427
45. Chakraborty M., Abrams S.I., Coleman C.N., et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64 (2004) 4328-4337
46. + cytotoxic T lymphocyte attack. Cancer Immunol Immunother 49 (2000) 193-207
47. Debbage P.L., Seidl S., Kreczy A., et al. Vascular permeability and hyperpermeability in a murine adenocarcinoma after fractionated radiotherapy: An ultrastructural tracer study. Histochem Cell Biol 114 (2000) 259-275
48. Coughlin C.M., Salhany K.E., Gee M.S., et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 (1998) 25-34
49. Kaminski J.M., Shinohara E., Summers J.B., et al. The controversial abscopal effect. Cancer Treat Rev 31 (2005) 159-172
50. Demaria S., Ng B., Devitt M.L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58 (2004) 862-870